Home > Publications Database > Cannabis sativa extracts reduce inclusion formation in a cell model of alpha-synuclein aggregation. > print

001     283017
005     20260217131413.0
024 7 _ |2 doi
|a 10.1016/j.fitote.2025.106968
024 7 _ |2 pmid
|a pmid:41187864
024 7 _ |2 ISSN
|a 0367-326X
024 7 _ |2 ISSN
|a 1873-6971
037 _ _ |a DZNE-2025-01429
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a de Almeida Cruz, Tamires
|b 0
245 _ _ |a Cannabis sativa extracts reduce inclusion formation in a cell model of alpha-synuclein aggregation.
260 _ _ |a Amsterdam [u.a.]
|b Elsevier Science
|c 2025
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1767360086_32511
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Parkinson's disease (PD) is classified as a synucleinopathy due to the accumulation of protein inclusions rich in the alpha-synuclein (aSyn) protein. Identifying effective pharmacological therapies is important to slow the progression and minimize the symptoms of these diseases. Cannabis sativa has a diverse chemical profile depending on its genotype, including several classes of substances, such as cannabinoids, flavonoids, terpenes, and alkaloids. In this study, we evaluated the effects of four C. sativa extracts with different phytocannabinoid chemical profiles in two cellular models that reproduce alterations in cellular homeostasis common during the cellular phase of PD and other synucleinopathies. We used Saccharomyces cerevisiae strains transformed with plasmid DNA and genetically modified human cells (H4), both expressing aSyn. The results showed that all the extracts were antioxidants, decreasing intracellular oxidation levels and increasing the number of daughter cells in yeast cells, but did not prevent mitochondrial damage. Besides, the extracts reduced the number of intracellular inclusions in H4 cells and increased the number of cells without inclusions. Phytochemical characterization revealed extracts rich in Tetrahydrocannabinol - THC (69.88 %), Cannabidiol - CBD (52.64 %), and Cannabinol - CBN (47.38 % and 58.64 %), and we concluded that, regardless of these percentages, all C. sativa extracts showed protective biological activity against toxicity caused by alpha-synuclein production, both in yeast cells and H4 cells.
536 _ _ |0 G:(DE-HGF)POF4-352
|a 352 - Disease Mechanisms (POF4-352)
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |2 Other
|a Alpha-synuclein
650 _ 7 |2 Other
|a Neurodegeneration
650 _ 7 |2 Other
|a Parkinson's disease, cannabis sativa
650 _ 7 |2 Other
|a Protein aggregation
650 _ 2 |2 MeSH
|a alpha-Synuclein: metabolism
650 _ 2 |2 MeSH
|a Cannabis: chemistry
650 _ 2 |2 MeSH
|a Humans
650 _ 2 |2 MeSH
|a Saccharomyces cerevisiae: drug effects
650 _ 2 |2 MeSH
|a Plant Extracts: pharmacology
650 _ 2 |2 MeSH
|a Plant Extracts: chemistry
650 _ 2 |2 MeSH
|a Cannabinoids: pharmacology
650 _ 2 |2 MeSH
|a Parkinson Disease: drug therapy
650 _ 2 |2 MeSH
|a Antioxidants: pharmacology
650 _ 2 |2 MeSH
|a Phytochemicals: pharmacology
700 1 _ |a de Paulo Osorio, Rodrigo
|b 1
700 1 _ |a de Menezes Epifanio, Neide Mara
|b 2
700 1 _ |a Merghani, Madiha
|b 3
700 1 _ |a Pereira, Marcos Dias
|b 4
700 1 _ |a de Almeida Chaves, Douglas Siqueira
|b 5
700 1 _ |0 P:(DE-2719)2814138
|a Outeiro, Tiago Fleming
|b 6
|u dzne
700 1 _ |a Riger, Cristiano Jorge
|b 7
773 _ _ |0 PERI:(DE-600)2027649-7
|a 10.1016/j.fitote.2025.106968
|g Vol. 188, p. 106968 -
|p 106968
|t Fitoterapia
|v 188
|x 0367-326X
|y 2025
856 4 _ |u https://pub.dzne.de/record/283017/files/DZNE-2025-01429_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/283017/files/DZNE-2025-01429_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:283017
|p VDB
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2814138
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 6
|k DZNE
913 1 _ |0 G:(DE-HGF)POF4-352
|1 G:(DE-HGF)POF4-350
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b FITOTERAPIA : 2022
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)9900
|2 StatID
|a IF < 5
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21